Sc.D., pharmacoepidemiology, Harvard School of Public Health; M.P.H., chronic disease epidemiology, Yale Medical School; B.S., pharmacy, Kaohsiung Medical College, Taiwan
Summary of Experience
Dr. Duh is a pharmacoepidemiologist specializing in the safety, health economics, and outcomes of pharmaceuticals and medical devices. She has published more than 110 articles in peer-reviewed journals in the areas of drug safety, health economics, outcomes research, patient reported outcomes, comparative effectiveness research, direct and indirect costs, and cost-effectiveness analysis, and has utilized data from clinical trials, literature, large health insurance claims databases, medical records review, patient surveys, and Medwatch spontaneous reports data. She has led research and publications for numerous pharmaceutical companies in the areas of health economics and outcomes research, the U.S. Food and Drug Administration's post-marketing commitment and post-marketing requirement studies, and the European Medicines Agency's post-authorization safety studies. Her work also includes pharmaceutical liability litigation and securities fraud litigation associated with adverse drug events that lead to product recall, market withdrawal, black box warnings, and FDA limited access programs.
Dr. Duh served as a chairperson for Drug Information Association annual meetings and was an adjunct assistant professor of pharmacoeconomics and pharmacoepidemiology at Massachusetts College of Pharmacy and Allied Health Sciences in Boston. She is a visiting scholar in the biostatistics department and a guest lecturer in the epidemiology department, both at the Harvard University School of Public Health. Dr. Duh was appointed to an expert panel convened by the Foundation for the National Institutes of Health's Observational Medical Outcomes Partnership (OMOP) to develop methodologies for studying drug-induced liver injuries on a national scale. She has served as a peer reviewer for several journals, including PharmacoEconomics, American Journal of Hospital-System Pharmacists, Chest, Pharmacoepidemiology and Drug Safety, American Journal of Kidney Diseases, and Therapeutics and Clinical Risk Management. Dr. Duh is also an elected member of the American Society of Hematology, and a member of the International Society of Pharmacoepidemiology and the International Society of Pharmacoeconomics and Outcomes Research.
View Dr. Duh's selected publications on the Harvard Catalyst website